PeerView Family Medicine & General Practice CME/CNE/CPE Audio Podcast

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups. For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/NQH865. CME/MOC/AAPA/IPCE credit will be available until April 21, 2025. New Chapters in the Immunotherapy Story for Melanoma: Collaborative Care and Next Steps With Adjuvant and Neoadjuvant Therapy In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. Support This activity is supported through educational grants from Bristol Myers Squibb and Merck & Co., Inc. Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups. For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC information, and to apply for credit, please visit us at PeerView.com/UVZ865. CME/MOC credit will be available until April 9, 2025. Navigating Narcolepsy in Family Practice: Patient-Centered Strategies to Optimize the Experience and Outcomes of Treatment In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. Support This activity is supported by an educational grant from Avadel CNS Pharmaceuticals, LLC. Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups. For the full presentation, downloadable Practice Aids, slides, and complete CME/NCPD/AAPA information, and to apply for credit, please visit us at PeerView.com/WMV865. CME/NCPD/AAPA credit will be available until March 25, 2025. Conversations With Peers About T2DM: Best Practices for Optimizing Treatment Using Weight Management as a Primary Goal In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. Support This activity is supported by an educational grant from Lilly. Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups. For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/SVX865. CME/MOC/AAPA credit will be available until March 7, 2025. Evolving Concepts in the Pathogenesis of Inflammatory Dermatologic Disorders and the Rationale for Targeted Biologic Therapy: Focus on Moderate to Severe Atopic Dermatitis, Prurigo Nodularis, Chronic Urticaria, and Bullous Pemphigoid In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. Support This activity is supported by an educational grant from Sanofi and Regeneron Pharmaceuticals. Disclosure Policy All relevant conflicts of interest have been mitigated prior to the commencement of the activity. Faculty/Planner Disclosures Co-Chair/Planner Adam Friedman, MD, FAAD, has a financial interest/relationship or affiliation in the form of: Consultant and/or Advisor for Arcutis Biotherapeutics, Inc.; Incyte; Janssen Pharmaceuticals, Inc.; and Regeneron Pharmaceuticals Inc./Sanofi. Grant/Research Support from Incyte and Janssen Pharmaceuticals, Inc. Speaker for Bristol Myers Squibb; Incyte; Janssen Pharmaceuticals, Inc.; and Regeneron Pharmaceuticals Inc./Sanofi. Co-Chair/Planner Shawn Kwatra, MD, has a financial interest/relationship or affiliation in the form of: Consultant and/or Advisor for AbbVie Inc.; Amgen Inc.; Arcutis Biotherapeutics, Inc.; Asian Pharmaceuticals Pvt. Ltd.; Bristol Myers Squibb; Cara Therapeutics; Castle Biosciences, Inc.; Celldex Therapeutics; Dermavant Sciences, Inc.; Galderma; Genzada Pharmaceuticals USA, Inc.; Incyte; Johnson & Johnson Services, Inc.; LEO Pharma A/S; Novartis Pharmaceuticals Corporation; Pfizer; Regeneron Pharmaceuticals Inc.; and Sanofi. Grant/Research Support from Galderma; Incyte; Pfizer; and Sanofi. Co-Chair/Planner Peter A. Lio, MD, has a financial interest/relationship or affiliation in the form of: Consultant and/or Advisor for AbbVie Inc.; Almirall, S.A.; Amyris, Inc.; AOBiome; ASLAN Pharmaceuticals Pte Ltd; Bristol Myers Squibb; Burt’s Bees Products Company; Concerto Biosciences; Dermavant Sciences, Inc.; Galderma S.A.; Leo Pharma Inc.; Lilly; L’Oréal USA, Inc.; Merck & Co., Inc.; Micreos B.V.; MyOR; Pfizer; Pierre Fabre group; Regeneron Pharmaceuticals Inc./Sanofi Genzyme; Theraplex; UCB, Inc.; and Verrica Pharmaceuticals. Grant/Research Support from AbbVie Inc. and Regeneron Pharmaceuticals Inc./Sanofi Genzyme. Speakers Bureau participant with AbbVie Inc.; Galderma S.A.; Incyte; Leo Pharma Inc.; Lilly; L’Oréal USA, Inc.; Pfizer; and Regeneron Pharmaceuticals Inc./Sanofi Genzyme. Co-Chair/Planner Professor Dedee Murrell has a financial interest/relationship or affiliation in the form of: Consultant and/or Advisor for Amryt Pharma plc; Castle Creek Biosciences, Inc.; Krystal Biotech; and RHEACELL GmbH & Co. KG. Planning Committee and Reviewer Disclosures Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups. For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/GJM865. CME/MOC/AAPA/IPCE credit will be available until March 12, 2025. A Joint Effort for Equitable Hemophilia A Care: Collaborative Solutions for Enhancing Outcomes in Diverse and Challenging Patient Populations In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. Support This activity is supported by educational grants from Genentech, a member of the Roche Group, and Novo Nordisk Inc. Disclosure Policy All relevant conflicts of interest have been mitigated prior to the commencement of the activity. Faculty/Planner Disclosures Chair/Planner Amy Shapiro, MD, has a financial interest/relationship or affiliation in the form of: Consultant and/or Advisor for Be Biopharma; BioMarin; Genentech, Inc./F. Hoffmann-La Roche Ltd; HEMA Biologics, LLC; Kedrion Biopharma Inc.; Novo Nordisk Inc.; Pfizer; and Sanofi-Genzyme. Grant/Research Support from Agios Pharmaceuticals, Inc.; BioMarin; Genentech, Inc./F. Hoffmann-La Roche Ltd; Kedrion Biopharma Inc.; Novo Nordisk Inc.; Pfizer; Regeneron Pharmaceuticals Inc.; Sanofi-Genzyme; Pharmacosmos A/S; and Takeda Pharmaceutical Company Limited. Speakers Bureau participant with Genentech, Inc./F. Hoffmann-La Roche Ltd; Kedrion Biopharma Inc.; and Sanofi-Genzyme. Other Financial or Material Support in the form as a board member of the Novo Nordisk Haemophilia Foundation. She is the Medical Director of the National Hemophilia Program and Coordinating Center of the American Thrombosis Hemostatis Network. Faculty/Planner Maissaa Janbain, MD, MSCR, has a financial interest/relationship or affiliation in the form of: Consultant and/or Advisor for AstraZeneca; Clovis Oncology, Inc.; Genentech, Inc.; GlaxoSmithKline; Novartis Pharmaceuticals Corporation; Pfizer; Puma Biotechnology, Inc.; Sanofi Genzyme; and Seagen Inc. Grant/Research Support from AstraZeneca; Pfizer; and Seagen Inc. Planning Committee and Reviewer Disclosures Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups. For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/AGP865. CME/MOC/AAPA credit will be available until March 7, 2025. Overcoming Challenges in the Treatment of Pediatric and Adult Patients With Uncontrolled Moderate to Severe Asthma: Comparing Approaches to the Use of Targeted Biologic Therapy With Experts Around the World In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. Support This activity is supported by an educational grant from Sanofi and Regeneron Pharmaceuticals. Disclosure Policy All relevant conflicts of interest have been mitigated prior to the commencement of the activity. Faculty/Planner Disclosures Chair/Planner Leonard B. Bacharier, MD, has a financial interest/relationship or affiliation in the form of: Consultant and/or Advisor for Aravax; AstraZeneca; Avillion LLP; DBV Technologies; GlaxoSmithKline; Kinaset Therapeutics; Regeneron Pharmaceuticals Inc.; Sanofi; and Vertex Pharmaceuticals Incorporated. Speaker for Regeneron Pharmaceuticals Inc. and Sanofi. Other Financial or Material Support for Patents and Royalties from Elsevier. Faculty/Planner Klaus F. Rabe, MD, PhD, FERS, has a financial interest/relationship or affiliation in the form of: Consultant and/or Advisor for AstraZeneca; BERLIN-CHEMIE AG; Boehringer Ingelheim International GmbH; CHIESI USA, Inc.; CSL Behring; Regeneron Pharmaceuticals Inc.; and Sanofi. Speakers Bureau participant with AstraZeneca; BERLIN-CHEMIE AG; Boehringer Ingelheim International GmbH; CHIESI USA, Inc.; The Menarini Group; Regeneron Pharmaceuticals Inc.; and Sanofi. Presenter Arzu Yorgancioglu, MD, has a financial interest/relationship or affiliation in the form of: Consultant and/or Advisor for Abdi İbrahim; AstraZeneca; CHIESI USA, Inc.; and GlaxoSmithKline. Grant/Research Support from Sanofi. Speaker for Abdi İbrahim; AstraZeneca; Bilim Pharmaceuticals; CHIESI USA, Inc.; GlaxoSmithKline; and Novartis Pharmaceuticals Corporation. Planning Committee and Reviewer Disclosures Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups. For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/AGP865. CME/MOC/AAPA credit will be available until March 7, 2025. Overcoming Challenges in the Treatment of Pediatric and Adult Patients With Uncontrolled Moderate to Severe Asthma: Comparing Approaches to the Use of Targeted Biologic Therapy With Experts Around the World In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. Support This activity is supported by an educational grant from Sanofi and Regeneron Pharmaceuticals. Disclosure Policy All relevant conflicts of interest have been mitigated prior to the commencement of the activity. Faculty/Planner Disclosures Chair/Planner Leonard B. Bacharier, MD, has a financial interest/relationship or affiliation in the form of: Consultant and/or Advisor for Aravax; AstraZeneca; Avillion LLP; DBV Technologies; GlaxoSmithKline; Kinaset Therapeutics; Regeneron Pharmaceuticals Inc.; Sanofi; and Vertex Pharmaceuticals Incorporated. Speaker for Regeneron Pharmaceuticals Inc. and Sanofi. Other Financial or Material Support for Patents and Royalties from Elsevier. Faculty/Planner Klaus F. Rabe, MD, PhD, FERS, has a financial interest/relationship or affiliation in the form of: Consultant and/or Advisor for AstraZeneca; BERLIN-CHEMIE AG; Boehringer Ingelheim International GmbH; CHIESI USA, Inc.; CSL Behring; Regeneron Pharmaceuticals Inc.; and Sanofi. Speakers Bureau participant with AstraZeneca; BERLIN-CHEMIE AG; Boehringer Ingelheim International GmbH; CHIESI USA, Inc.; The Menarini Group; Regeneron Pharmaceuticals Inc.; and Sanofi. Presenter Arzu Yorgancioglu, MD, has a financial interest/relationship or affiliation in the form of: Consultant and/or Advisor for Abdi İbrahim; AstraZeneca; CHIESI USA, Inc.; and GlaxoSmithKline. Grant/Research Support from Sanofi. Speaker for Abdi İbrahim; AstraZeneca; Bilim Pharmaceuticals; CHIESI USA, Inc.; GlaxoSmithKline; and Novartis Pharmaceuticals Corporation. Planning Committee and Reviewer Disclosures Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups. For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/AGP865. CME/MOC/AAPA credit will be available until March 7, 2025. Overcoming Challenges in the Treatment of Pediatric and Adult Patients With Uncontrolled Moderate to Severe Asthma: Comparing Approaches to the Use of Targeted Biologic Therapy With Experts Around the World In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. Support This activity is supported by an educational grant from Sanofi and Regeneron Pharmaceuticals. Disclosure Policy All relevant conflicts of interest have been mitigated prior to the commencement of the activity. Faculty/Planner Disclosures Chair/Planner Leonard B. Bacharier, MD, has a financial interest/relationship or affiliation in the form of: Consultant and/or Advisor for Aravax; AstraZeneca; Avillion LLP; DBV Technologies; GlaxoSmithKline; Kinaset Therapeutics; Regeneron Pharmaceuticals Inc.; Sanofi; and Vertex Pharmaceuticals Incorporated. Speaker for Regeneron Pharmaceuticals Inc. and Sanofi. Other Financial or Material Support for Patents and Royalties from Elsevier. Faculty/Planner Klaus F. Rabe, MD, PhD, FERS, has a financial interest/relationship or affiliation in the form of: Consultant and/or Advisor for AstraZeneca; BERLIN-CHEMIE AG; Boehringer Ingelheim International GmbH; CHIESI USA, Inc.; CSL Behring; Regeneron Pharmaceuticals Inc.; and Sanofi. Speakers Bureau participant with AstraZeneca; BERLIN-CHEMIE AG; Boehringer Ingelheim International GmbH; CHIESI USA, Inc.; The Menarini Group; Regeneron Pharmaceuticals Inc.; and Sanofi. Presenter Arzu Yorgancioglu, MD, has a financial interest/relationship or affiliation in the form of: Consultant and/or Advisor for Abdi İbrahim; AstraZeneca; CHIESI USA, Inc.; and GlaxoSmithKline. Grant/Research Support from Sanofi. Speaker for Abdi İbrahim; AstraZeneca; Bilim Pharmaceuticals; CHIESI USA, Inc.; GlaxoSmithKline; and Novartis Pharmaceuticals Corporation. Planning Committee and Reviewer Disclosures Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups. For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/AGP865. CME/MOC/AAPA credit will be available until March 7, 2025. Overcoming Challenges in the Treatment of Pediatric and Adult Patients With Uncontrolled Moderate to Severe Asthma: Comparing Approaches to the Use of Targeted Biologic Therapy With Experts Around the World In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. Support This activity is supported by an educational grant from Sanofi and Regeneron Pharmaceuticals. Disclosure Policy All relevant conflicts of interest have been mitigated prior to the commencement of the activity. Faculty/Planner Disclosures Chair/Planner Leonard B. Bacharier, MD, has a financial interest/relationship or affiliation in the form of: Consultant and/or Advisor for Aravax; AstraZeneca; Avillion LLP; DBV Technologies; GlaxoSmithKline; Kinaset Therapeutics; Regeneron Pharmaceuticals Inc.; Sanofi; and Vertex Pharmaceuticals Incorporated. Speaker for Regeneron Pharmaceuticals Inc. and Sanofi. Other Financial or Material Support for Patents and Royalties from Elsevier. Faculty/Planner Klaus F. Rabe, MD, PhD, FERS, has a financial interest/relationship or affiliation in the form of: Consultant and/or Advisor for AstraZeneca; BERLIN-CHEMIE AG; Boehringer Ingelheim International GmbH; CHIESI USA, Inc.; CSL Behring; Regeneron Pharmaceuticals Inc.; and Sanofi. Speakers Bureau participant with AstraZeneca; BERLIN-CHEMIE AG; Boehringer Ingelheim International GmbH; CHIESI USA, Inc.; The Menarini Group; Regeneron Pharmaceuticals Inc.; and Sanofi. Presenter Arzu Yorgancioglu, MD, has a financial interest/relationship or affiliation in the form of: Consultant and/or Advisor for Abdi İbrahim; AstraZeneca; CHIESI USA, Inc.; and GlaxoSmithKline. Grant/Research Support from Sanofi. Speaker for Abdi İbrahim; AstraZeneca; Bilim Pharmaceuticals; CHIESI USA, Inc.; GlaxoSmithKline; and Novartis Pharmaceuticals Corporation. Planning Committee and Reviewer Disclosures Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups. For the full presentation, downloadable Practice Aids, slides, and complete CME/AAPA information, and to apply for credit, please visit us at PeerView.com/QHE865. CME/AAPA credit will be available until February 21, 2025. Activating Better Care in SCD: Guidance on Novel PKR Agents, Other Innovative Therapies, and Modern Care Transitions In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and Sickle Cell Disease Association of America, Inc. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. Support This activity is supported by an educational grant from Novo Nordisk Inc. Disclosure Policy All relevant conflicts of interest have been mitigated prior to the commencement of the activity. Faculty/Planner Disclosures Chair/Planner Santosh L. Saraf, MD, has a financial interest/relationship or affiliation in the form of: Consultant and/or Advisor for Agios Pharmacueticals, Inc.; Global Blood Therapeutics, Inc.; Novartis Pharmaceuticals Corporation; Novo Nordisk, Inc.; and Pfizer. Grant/Research Support from Global Blood Therapeutics, Inc.; Novartis Pharmaceuticals Corporation; and Pfizer. Planning Committee and Reviewer Disclosures Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups. For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/CGE865. CME/MOC/AAPA/IPCE credit will be available until February 28, 2025. REVIVE Initiative: Reinforcing Evidence-Based Principles Against Cancer-Associated Venous Thromboembolism In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. Support This activity is supported by an educational grant from the Bristol Myers Squibb and Pfizer Alliance. Disclosure Policy All relevant conflicts of interest have been mitigated prior to the commencement of the activity. Faculty/Planner Disclosures Chair/Planner Alok A. Khorana, MD, FACP, FASCO, has a financial interest/relationship or affiliation in the form of: Consultant and/or Advisor for Anthos Therapeutics; Bayer Corporation; Bristol Myers Squibb; Pfizer; and Sanofi. Planning Committee and Reviewer Disclosures Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups. For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/GVK865. CME credit will be available until February 13, 2025. Targeting Elevated Cardiovascular Risk: Current Therapies and New Horizons in Hyperlipidemia Management The University of Florida College of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. This activity is developed in collaboration with our educational partner, PVI, PeerView Institute for Medical Education. Support This activity is supported by an educational grant from Novartis Pharmaceuticals Corporation. Disclosures R. Scott Wright, MD, has a financial interest/relationship or affiliation in the form of: Consultant and/or Advisor for Boehringer Ingelheim Pharmaceuticals, Inc.; Novartis Pharmaceuticals Corporation; and Novo Nordisk Inc. CME Reviewer Ramil Goel Assistant Professor of Medicine Division of Cardiovascular Medicine Electrophysiology Section University of Florida College of Medicine Gainesville, Florida Ramil Goel, MD, FHRS, has no relevant financial relationships to disclose.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups. For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/DXM865. CME/MOC/AAPA credit will be available until February 12, 2025. Targeting a Brighter Future for Pediatric Patients With Eosinophilic Esophagitis: Ensuring Prompt Diagnosis and Exploring the Role of Biologic Treatment In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and Campaign Urging Research for Eosinophilic Disease. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. Support This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc and Sanofi. Disclosure Policy All relevant conflicts of interest have been mitigated prior to the commencement of the activity. Faculty/Planner Disclosures Chair/Planner Joshua B. Wechsler, MD, MSci, has a financial interest/relationship or affiliation in the form of: Consultant and/or Advisor for AstraZeneca; Bristol Myers Squibb; Ellodi Pharmaceuticals; Regeneron Pharmaceuticals, Inc; and Sanofi. Grant/Research Support from Regeneron Pharmaceuticals, Inc and Sanofi. Speaker for Regeneron Pharmaceuticals, Inc and Sanofi. Patient Advocate/Planner Holly Roland has no financial interests/relationships or affiliations in relation to this activity. Planning Committee and Reviewer Disclosures Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups. For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/AAPA information, and to apply for credit, please visit us at PeerView.com/QYG865. CME/MOC/NCPD/AAPA credit will be available until January 21, 2025. Calling Primary Care Partners to Action in Hypertrophic Cardiomyopathy: Shortening the Time to Diagnosis for Improved Patient Outcomes In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. Support This activity is supported through an educational grant from Bristol Myers Squibb. Disclosure Policy All relevant conflicts of interest have been mitigated prior to the commencement of the activity. Faculty/Planner Disclosures Chair/Planner Anjali Tiku Owens, MD, has a financial interest/relationship or affiliation in the form of: Consultant and/or Advisor for BioMarin; Bristol Myers Squibb; Cytokinetics; Edgewise Therapeutics; Lexicon Pharmaceuticals, Inc.; Pfizer; Renovacor, Inc.; Stealth BioTherapeutics Inc.; and Tenaya Therapeutics. Grant/Research Support from Bristol Myers Squibb. Faculty/Planner Neil Skolnik, MD, has a financial interest/relationship or affiliation in the form of: Consultant and/or Advisor for Abbott; Astellas Pharma Inc.; AstraZeneca; Bayer Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; Genentech, Inc.; GSK; Idorsia Pharmaceuticals Ltd; Lilly; Novo Nordisk; Sanofi; and Teva Pharmaceuticals USA, Inc. Grant/Research Support from AstraZeneca; GSK; and Novo Nordisk. Speaker for Astellas Pharma Inc.; AstraZeneca; Bayer Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; Heartland Pharma; GSK; Lilly; and Teva Pharmaceuticals USA, Inc. Planning Committee and Reviewer Disclosures Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups. For the full presentation, downloadable Practice Aids, slides, and complete CME/NCPD/CPE/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/YHX865. CME/NCPD/CPE/AAPA/IPCE credit will be available until December 12, 2024. Getting Personal: Reassessing HIV Management to Better Individualize Treatment Across the Ages In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. Support This program has been supported by an independent educational grant from Gilead Sciences, Inc. Disclosure Policy All relevant conflicts of interest have been mitigated prior to the commencement of the activity. Faculty/Planner Disclosures Chair/Planner Professor Chloe Orkin has a financial interest/relationship or affiliation in the form of: Consultant and/or Advisor for Gilead Sciences, Inc.; GSK; Merck Sharp & Dohme; and ViiV Healthcare group of companies. Grant/Research Support from Gilead Sciences, Inc. and ViiV Healthcare group of companies. Speaker for Gilead Sciences, Inc.; GSK; Merck Sharp & Dohme; and ViiV Healthcare group of companies. Patient Advocate/Planner Shawnte' Spriggs has no financial interests/relationships or affiliations in relation to this activity. Patient Advocate/Planner Donald Young has no financial interests/relationships or affiliations in relation to this activity. Planning Committee and Reviewer Disclosures Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups. For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/VQT865. CME/MOC/AAPA credit will be available until December 18, 2024. Beyond Airway Inflammation: Examining the Potential Clinical Utility of Mucus Plugging and Airway Hyperresponsiveness in Severe Asthma to Assess Severity and Guide Biologic Treatment In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. Support This activity is supported by an independent educational grant from AstraZeneca LP. Disclosure Policy All relevant conflicts of interest have been mitigated prior to the commencement of the activity. Faculty/Planner Disclosures Co-Chair/Planner Jonathan Corren, MD, has a financial interest/relationship or affiliation in the form of: Consultant and/or Advisor for AstraZeneca; Regeneron Pharmaceuticals Inc.; and Sanofi. Grant/Research Support from AstraZeneca; Novartis Pharmaceuticals Corporation; Regeneron Pharmaceuticals Inc.; and Sanofi. Speaker for AstraZeneca; Regeneron Pharmaceuticals Inc.; and Sanofi. Co-Chair/Planner Mario Castro, MD, has a financial interest/relationship or affiliation in the form of: Consultant and/or Advisor for Allakos Inc.; Amgen Inc.; Arrowhead Pharmaceuticals, Inc.; Genentech, Inc.; GSK; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation; OM Pharma Ltd.; Pfizer; Pioneering Medicines; Sanofi-Aventis; and Teva Pharmaceuticals USA, Inc. Grant/Research Support from American Lung Association (ALA); AstraZeneca; Gala Therapeutics, Inc.; Genentech, Inc.; GSK; National Institutes of Health (NIH); Novartis Pharmaceuticals Corporation; Patient-Centered Outcomes Research Institute (PCORI); Pulmatrix, Inc.; Sanofi-Aventis; Shionogi & Co., Ltd; and Theravance Biopharma. Speaker for Amgen Inc.; AstraZeneca; Genentech, Inc.; Regeneron Pharmaceuticals Inc.; Sanofi-Aventis; and Teva Pharmaceuticals USA, Inc. Stock Shareholder in Aer Therapeutics. Planning Committee and Reviewer Disclosures Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups. For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/JXH865. CME credit will be available until December 31, 2024. Toward a Brighter Future for Preventing COVID-19 in Patients With Hematologic Malignancies: Leveraging the Power of Current Strategies and Next-Generation Agents Penn State College of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. This activity is developed in collaboration with our educational partner, PVI, PeerView Institute for Medical Education. Support This activity is supported by an independent educational grant from AstraZeneca LP. Disclosures Shmuel Shoham, MD, has a financial interest/relationship or affiliation in the form of: Consultant and/or Advisor for Adagio Therapeutics, Inc.; Adamis Pharmaceuticals Corporation; Immunome; Karius, Inc.; Pfizer; and SCYNEXIS, Inc. Grant/Research Support from Ansun Biopharma; Cidara Therapeutics, Inc.; F2G; Octapharma USA, Inc.; and Zeteo Biomedical LLC. Ghady Haidar, MD, has a financial interest/relationship or affiliation in the form of: Consultant and/or Advisor for AstraZeneca and Karius, Inc. Grant/Research Support from Allovir; AstraZeneca; Karius, Inc.; and National Institutes of Health (NIH). Speaker for International AIDS Society and MDOutlook. Carol Ann Huff, MD, has a financial interest/relationship or affiliation in the form of: Consultant and/or Advisor for Janssen Pharmaceuticals, Inc. and Sanofi. Haleh Simi has no financial interests/relationships or affiliations in relation to this activity. Other PVI staff who may potentially review content for this activity have disclosed no relevant financial relationships. Penn State College of Medicine staff and faculty involved in the development and review of this activity have disclosed no relevant financial relationships. All of the relevant financial relationships listed for these individuals have been mitigated.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups. For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/DDA865. CME credit will be available until December 26, 2024. At the Heart of Obesity: Evidence-Based Strategies for Managing Obesity to Reduce Cardiovascular Risks With Weight Loss Pharmacotherapy In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. Support This activity is supported by an educational grant from Novo Nordisk Inc. Disclosure Policy All relevant conflicts of interest have been mitigated prior to the commencement of the activity. Faculty/Planner Disclosures Chair/Planner Jorge Plutzky, MD, has no financial interests/relationships or affiliations in relation to this activity. Planning Committee and Reviewer Disclosures Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

Go online to PeerView.com/DRZ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Atopic dermatitis (AD) carries a significant disease burden, and evidence shows there is often a mismatch in perception of disease severity between patients and their providers. Further, the treatment landscape is complex, with multiple approved therapies, including targeted biologic agents, which have revitalized treatment of the disease. Along with patient vignettes and a 3D-animated video clip, this activity features AD experts discussing the assessment of severity in AD, the underlying pathophysiology of AD, and the role of targeted therapy in reducing AD flares and achieving and maintaining control of the disease. Upon completion of this activity, participants should be better able to: Recognize the significant burden of moderate to severe atopic dermatitis (AD) on patients, including the impact of itch, depression, sleep disturbance, anxiety, and treatment dissatisfaction; Describe underlying mechanisms, including immunological and epidermal barrier dysfunction, that contribute to the development of AD and provide rationale for the use of targeted biologic therapy; and Select treatment for patients with moderate to severe AD, including biologic agents as appropriate, according to recent clinical evidence and current guidelines, with a goal of minimizing/preventing flares.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups. For the full presentation, downloadable Practice Aids, slides, and complete CME/CPD information, and to apply for credit, please visit us at PeerView.com/BVW865. CME/CPD credit will be available until December 27, 2024. Tools of the Trade: Prioritising Weight Management in People With Type 2 Diabetes – Sharpening Your Skills to Intensify Therapy and Engage in Shared Decision-Making In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. Support This activity is supported by an educational grant from Lilly. Disclosure Policy All relevant conflicts of interest have been mitigated prior to the commencement of the activity. Faculty/Planner Disclosures Chair/Planner Stefano Del Prato, MD, has a financial interest/relationship or affiliation in the form of: Consultant and/or Advisor for Abbott; Amarin Corporation plc; Applied Therapeutics; EvaPharma; Lilly; The Menarini Group; Novo Nordisk A/S; Sanofi; and Sun Pharmaceutical Industries Ltd. Speaker for Abbott; AstraZeneca; Berlin-Chemie AG; Boehringer Ingelheim International GmbH; Laboratori Guidotti S.p.a.; Lilly; The Menarini Group; Merck Sharp & Dohme; and Novo Nordisk A/S. Planning Committee and Reviewer Disclosures Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.